Medicare drug coverage

Combivent: 2027 Medicare Part D coverage

5,495 of 5,495 Part D plans (100%) list Combivent on their 2027 formulary, the same share as 2026. 98% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Combivent is number 113 by total Medicare Part D spending in 2024 ($388 million). Plans that list it most often put it on tier 4. Counts use 2 RxNorm products for this name.

Combivent Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,517 (100%)5,495 (100%)no change
Prior authorization (of plans that list it)0 (0%)0 (0%)no change
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)5,383 (98%)5,376 (98%)no change
Any of the three (of plans that list it)5,383 (98%)5,376 (98%)no change
Not listed or restricted (of all plans)5,384 (98%)5,376 (98%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Combivent formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1163 (3%)123 (2%)
Tier 210 (0%)276 (5%)
Tier 32,228 (40%)1,888 (34%)
Tier 43,116 (56%)3,208 (58%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 5 of them (0%) added prior authorization, step therapy, or a quantity limit for Combivent, and 0 stopped listing it.

Combivent: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 20270 (0%)
Listed it in 2027, not in 20260 (0%)
Moved it to a higher tier62 (1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit5 (0%)
Added at least one of the three5 (0%)
Removed at least one of the three1 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Combivent off the formulary or list it with prior authorization, step therapy, or a quantity limit. Alaska ranks first at 100%, with 0% of its plans using prior authorization or step therapy; Maryland ranks last at 80%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Combivent, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Alaska9100%0%no change
2Alabama115100%0%no change
3Arkansas86100%0%no change
4Arizona148100%0%no change
5Connecticut54100%0%no change
6Delaware43100%0%no change
7Florida549100%0%no change
8Iowa64100%0%no change
9Idaho45100%0%no change
10Illinois133100%0%no change
11Indiana140100%0%no change
12Kansas84100%0%no change
13Kentucky123100%0%no change
14Louisiana126100%0%no change
15Massachusetts92100%0%no change
16Maine52100%0%no change
17Michigan183100%0%no change
18Minnesota63100%0%+10 points
19Missouri171100%0%no change
20Mississippi105100%0%no change
21Montana27100%0%no change
22North Carolina177100%0%no change
23North Dakota26100%0%no change
24Nebraska51100%0%no change
25New Hampshire25100%0%no change
26New Jersey74100%0%no change
27New Mexico68100%0%no change
28Ohio173100%0%no change
29Oklahoma81100%0%no change
30Pennsylvania324100%0%no change
31Rhode Island29100%0%no change
32South Carolina91100%0%no change
33South Dakota30100%0%no change
34Tennessee157100%0%no change
35Texas412100%0%no change
36Utah53100%0%no change
37Vermont14100%0%no change
38West Virginia70100%0%no change
39Wyoming13100%0%no change
40Wisconsin9799%0%+2 points
41New York21597%0%no change
42Nevada10097%0%-3 points
43Virginia14596%0%no change
44Oregon9296%0%no change
45Georgia15195%0%no change
46Colorado10690%0%+3 points
47Hawaii5088%0%+1 point
48California39788%0%no change
49Washington11486%0%+1 point
50District of Columbia2186%0%-2 points
51Maryland4980%0%-5 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Combivent off or restrict it.

Combivent coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
BrightSpring Health Services, Inc.2100%100%100%no change0
Community Health Group2100%100%100%no change0
Community Health Plan of Washington2100%100%100%no change0
Denver Health and Hospital Authority2100%100%100%no change0
Elevance Health, Inc. & BCBSMA & BCBSRI & BCBSVT2100%100%100%no change0
Elite Health Systems, Inc.2100%100%100%no change0
Group Health Cooperative of Eau Claire2100%100%100%no change0
Hamaspik of Rockland County, Inc.2100%100%100%no change0
ISNP Holdings, LLC2100%100%100%no change0
Kansas Superior Select2100%100%100%no change0
Missouri Healthcare Advisors, LLC2100%100%100%no change0
MultiCare Health Systems2100%100%100%new in 20270
NEIGHBORHOOD HEALTH PLAN OF RHODE ISLAND2100%100%100%no change0
PrimeWest Rural MN Health Care Access Initiative2100%100%100%no change0
Regency ISNP Holdings LLC2100%100%100%no change0
Select Founders, LLC2100%100%100%no change0
Sentara Health Care (SHC)2100%100%100%no change0
South Country Health Alliance2100%100%100%no change0
The Regents of the University of California2100%100%100%no change0
Troy Holdings, Inc.2100%100%100%no change0
Associated Care Ventures, Inc.3100%100%100%no change0
Aultman Health Foundation3100%100%100%no change0
Banner Health3100%100%100%no change0
Bexar County Hospital District3100%100%100%no change0
Blue Cross Blue Shield of Nebraska3100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Combivent?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing